KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks
KVD900 Generally Safe and Well-Tolerated -
Conference Call to Discuss Trial Results Today at 8:30 a.m. ET -
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced positive topline data from a Phase 2 clinical trial demonstrating statistically and clinically significant efficacy of KVD900 as an oral on-demand treatment for hereditary angioedema (HAE) attacks. We are very excited to share this positive data which shows that KVD900 is the first oral therapy to achieve clinical efficacy results comparable to current injectable therapies, while also demonstrating a promising safety and tolerability profile.
Berentzen-Gruppe Aktiengesells
Berentzen‐Gruppe Aktiengesellschaft: Preliminary business figures for the 2020 financial year / Forecast for the 2021 financial year
DGAP-Ad-hoc: Berentzen-Gruppe Aktiengesellschaft / Key word(s): Preliminary Results/Forecast
Berentzen‐Gruppe Aktiengesellschaft: Preliminary business figures for the 2020 financial year / Forecast for the 2021 financial year
03-Feb-2021 / 18:12 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014
Haselünne, February 3, 2021
Berentzen-Gruppe Aktiengesellschaft: Preliminary business figures for the 2020 financial year / Forecast for the 2021 financial year
Cytokinetics Announces Recipients of Third Annual Communications Fellowship Grants
Total of $100,000 Awarded to Five Organizations to Support Communications and Community Outreach
SOUTH SAN FRANCISCO, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its third annual Communications Fellowship Grant program, intended to support increased capacity in communications, awareness building and community engagement for nonprofit organizations.
Five grants in the amount of $20,000 each were awarded this year to patient advocacy organizations serving the heart failure, hypertrophic cardiomyopathy (HCM) and amyotrophic lateral sclerosis (ALS) communities. The grants will support projects to increase awareness, reach underserved populations, provide assistive technologies to those in need, foster community connections and encourage education.
Wolters Kluwer N.V.: Share Buyback Transaction Details January 21 - 27, 2021
January 28, 2021 -
Wolters Kluwer today reports that it has repurchased 99,498 of its own ordinary shares in the period from January 21, 2021, up to and including January 27, 2021, for €6.9 million and at an average share price of €69.79.
These repurchases are part of the share buyback program announced on October 30, 2020, under which we intend to repurchase shares for up to €50 million during the period starting January 4, 2021, up to and including February 22, 2021.
The cumulative amounts repurchased to date under this program are as follows:
Share Buyback 2021
Total consideration
69.91
For the above-mentioned period, we have engaged a third party to execute €50 million of buybacks on our behalf, within the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and the company s Articles of Association.